Gain Therapeutics, Inc.

NasdaqGM GANX

Gain Therapeutics, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -2.58

Gain Therapeutics, Inc. Price to Earnings Ratio (P/E) is -2.58 on January 14, 2025, a 2.78% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Gain Therapeutics, Inc. 52-week high Price to Earnings Ratio (P/E) is -0.83 on August 13, 2024, which is 67.76% above the current Price to Earnings Ratio (P/E).
Gain Therapeutics, Inc. 52-week low Price to Earnings Ratio (P/E) is -3.67 on February 09, 2024, which is -42.03% below the current Price to Earnings Ratio (P/E).
Gain Therapeutics, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -2.08.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGM: GANX

Gain Therapeutics, Inc.

CEO	Mr. Gene Mack M.B.A.
IPO Date	March 19, 2021
Location	United States
Headquarters	4800 Montgomery Lane
Employees	29
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Key trends

Past 5 years